Lemmi - Based on the AHA data, Evaporate already succeeded (in a sense). Their primary outcome they picked prior to doing the study "failed" at the interim and is unlikely to be significant even after another 9 months (there was basically no effect). All the other measures were already significant, and will remain so. The pattern is more or less locked in. Despite technical "failure," this will be published and they will conclude that V slows plaque progression, which will still be important clinically and scientifically.
Market Data 
Markets 
AI
